Predictors of Long-Term Survival After Liver Transplantation for Metastatic Endocrine Tumors: An 85-Case French Multicentric Report

Treut, Y. P. Le; Grégoire, Émilie; Belghiti, Jacques; Boillot, Olivier; Soubrane, Olivier; Mantion, Georges; Cherqui, Daniel; Castaing, Denis; Ruszniewski, Philippe; Wolf, Philippe; Paye, François; Salamé, Ephrem; Muscari, Fabrice; Pruvot, François‐René; Baulieux, J.

doi:10.1111/j.1600-6143.2008.02233.x

Cited by 163 publications

(153 citation statements)

References 31 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…While nonresectable extrahepatic tumor manifestation, Ki-67% O15%, and severe carcinoid heart disease are generally accepted as exclusion criteria for LT, patient age (!50 vs O50 years), the dynamics of the hepatic tumor growth (stable disease vs rapid tumor progress), the extent of hepatic involvement, and timing of transplantation (first-line treatment vs an ultima ratio approach after unsuccessful previous treatment) remain controversial (Olausson et al 2002, Rosenau et al 2002, Le Treut et al 2008. Although encouraging overall 5-year survival rates of 50-90% have been reported in newer series, disease recurrence within 2-3 years after LT is to be expected (Frilling et al 2006, van Vilsteren et al 2006, Olausson et al 2007.…”

Section: R170mentioning

confidence: 99%

Neuroendocrine tumor disease: an evolving landscape

Frilling

Åkerström

Falconi

et al. 2012

Endocrine-Related Cancer

148

106

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) represent a heterogenous group of tumors arising from a variety of neuroendocrine cell types. The incidence and prevalence of GEPNENs have markedly increased over the last three decades. Symptoms are often absent in early disease, or vague and nonspecific even in advanced disease. Delayed diagnosis is thus common. Chromogranin A is the most commonly used biomarker but has limitations as does the proliferative marker Ki-67%, which is often used for tumor grading and determination of therapy. The development of a multidimensional prognostic nomogram may be valuable in predicting tumor behavior and guiding therapy but requires validation. Identification of NENs that express somatostatin receptors (SSTR) allows for SSTR scintigraphy and positron emission tomography imaging using novel radiolabeled compounds. Complete surgical resection of limited disease or endoscopic ablation of small lesions localized in stomach or rectum can provide cure; however, the majority of GEP-NENs are metastatic (most frequently the liver and/or mesenteric lymph nodes) at diagnosis. Selected patients with metastatic disease may benefit from advanced surgical techniques including hepatic resection or liver transplantation. Somatostatin analogs are effective for symptomatic treatment and exhibit some degree of antiproliferative activity in small intestinal NENs. There is a place for streptozotocin, temozolomide, and capecitabine in the management of pancreatic NENs, while new agents targeting either mTOR (everolimus) or angiogenic (sunitinib) pathways have shown efficacy in these lesions.

show abstract

Section: R170mentioning

confidence: 99%

Neuroendocrine tumor disease: an evolving landscape

Frilling

Åkerström

Falconi

et al. 2012

Endocrine-Related Cancer

148

106

View full text Add to dashboard Cite

show abstract

“…The significant factors included older age (>50 years 3 to 55 years 8 ), concomitant radical resections 3,8,10 , hepatomegaly 8 , and pancreatic or duodenal primaries 8 , all of which were associated with poor long-term outcomes. Here, we propose criteria (Table ii) in addition to those used in the Mayo Clinic study.…”

Section: Discussionmentioning

confidence: 99%

“…Three multicenter reviews 5,8,10 and a retrospective review of the United Network for Organ Sharing (unos) database 9 reported the prognostic factors associated with long-term survival ( Table i). The long-term survivals reported in those reviews were quite similar: between 44% and 49% at 5 years post transplantation.…”

Section: Introductionmentioning

confidence: 99%

Liver Transplantation for Symptomatic Liver Metastases of Neuroendocrine Tumours

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Thus, liver transplantation may be indicated in highly selected patients to provide immediate relief of otherwise intractable pain or hormone-related symptoms. OLT has no clear role in the routine treatment of patients with NET due to relatively high rates of tumor recurrence [9][10][11].…”

Section: Liver Transplantationmentioning

confidence: 99%

Long-term Survival in Patient with Metastatic Pancreatic Neuroendocrine Tumor Treated by Variable Treatment

Kang¹,

Ryu²,

Lee³

et al. 2017

Korean J Pancreas Biliary Tract

View full text Add to dashboard Cite

Well-to-moderately differentiated neuroendocrine tumors of gastroesophageal and pancreatic origin (GEP-NETs) with liver metastasis are a heterogeneous group of malignancies for which a range of therapeutic options have been employed. Surgical resection of hepatic metastases or hepatic artery embolization may be beneficial in patients with hepatic-predominant metastatic disease. Patients with "carcinoid" syndrome and syndromes associated with functional pancreatic NET (PNET) can be effectively treated with somatostatin analogs. On the other hand, the efficacy of systemic chemotherapy for these patients is limited. A placebo-controlled, double-blind, prospective, and randomized study showed that octreotide LAR improves progression-free survival in patients with advanced midgut functional "carcinoids." In patients with advanced pancreatic NET, randomized, placebo-controlled studies have recently demonstrated that treatment with the tyrosine kinase inhibitor sunitinib or with mTOR inhibitor everolimus is associated with improved progression-free survival. Based on these studies, octreotide LAR, sunitinib, or everolimus are now considered as first-line therapeutic options in patients with advanced NET. Future studies will likely further define the role of these agents in patients with carcinoid liver metastasis and pancreatic NET liver metastasis.

show abstract

Predictors of Long-Term Survival After Liver Transplantation for Metastatic Endocrine Tumors: An 85-Case French Multicentric Report

Cited by 163 publications

References 31 publications

Neuroendocrine tumor disease: an evolving landscape

Neuroendocrine tumor disease: an evolving landscape

Liver Transplantation for Symptomatic Liver Metastases of Neuroendocrine Tumours

Long-term Survival in Patient with Metastatic Pancreatic Neuroendocrine Tumor Treated by Variable Treatment

Contact Info

Product

Resources

About